On 20–21 November 2024, the PROMINENT consortium held its second annual meeting in Barcelona, hosted by Fundación Pasqual Maragall. Representatives from all 18 partner organisations reviewed progress and planned next steps for advancing precision medicine in neurodegenerative diseases. Project co-coordinator Linus Jönsson (Karolinska Institutet) opened with highlights from the past year, including the European Medicines Agency’s recommendation for Lecanemab and the addition of three partners, who followed with presentations on their contributions. Xin Xia (Karolinska Institutet) and Ferran Lugo (BarcelonaBeta Brain Research Center) shared updates on prediction models and diagnostic algorithms.
Jyrki Lötjönen (Combinostics) showcased progress on PROMINENT’s digital platform, incorporating feedback from the Advisory Board to align with clinician and patient needs. Day one concluded with presentations by Frank Jessen (Uniklinik Köln) on anti-amyloid therapies and Sandar Aye (Karolinska Institutet) on a dashboard to visualise the number of eligible patients for amyloid-targeting therapies across Europe. Day two featured Sofie Persson (IHE) on real-world evidence in health technology evaluation and Lena Sannemann (Uniklinik Köln) on validating the digital platform for specialists and patients.
Lennart Thurfjell (Combinostics) outlined private sector contributions, while Christophe Bintener (Alzheimer Europe) and Sébastien Libert (Alzheimer Europe) presented on communication activities and Public Involvement, respectively. Andrea Martí del Rio (SYNAPSE) and Anna Hansson (Karolinska Institutet) concluded with updates on project management, confirming milestones are on track. Linus Jönsson formally closed the meeting, thanking attendees and wishing them safe travels. Find out more about the project: www.ihi-prominent.eu